Certolizumab Pegol Treatment in Three Patients With Takayasu Arteritis

Objective & Hypothesis:Although glucocorticoids are the mainstay of treatment in Takayasu arteritis (TA), anti-tumor necrosis factor agents are other treatment options in refractory disease.

📊

Key Findings & Data:The onset of TA is generally observed in females of reproductive age.

💡

Conclusion & Impact:While two patients benefited from CZP, one patient was refractory to CZP.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Özet

Although glucocorticoids are the mainstay of treatment in Takayasu arteritis (TA), anti-tumor necrosis factor agents are other treatment options in refractory disease. The onset of TA is generally observed in females of reproductive age. Certolizumab pegol (CZP) lacks a fragment crystallizable region and this gives advantage of minimal transfer through the placenta, which makes CZP a safer option in pregnancy. Although there are case reports and trials about use of infliximab, etanercept, and adalimumab in TA, there are scarce data about use of CZP. In this article, we present three TA cases treated with CZP. While two patients benefited from CZP, one patient was refractory to CZP.

🔖

Cite This Article

ATAŞ, N., VARAN, Ö., BABAOĞLU, H., SATIŞ, H., SALMAN, R. B., TUFAN, A. (2019). Certolizumab Pegol Treatment in Three Patients With Takayasu Arteritis. art, Cilt: 34 - Sayı: 3, 357–362. https://ajindex.com/articles/147372

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (14)

Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1-11
Bicakcigil M, Aksu K, Kamali S, Ozbalkan Z, Ates A, Karadag O, et al. Takayasu’s arteritis in Turkey - clinical and angiographic features of 248 patients. Clin Exp Rheumatol 2009;27:59-64
Watts R, Al-Taiar A, Mooney J, Scott D, Macgregor A. The epidemiology of Takayasu arteritis in the UK. Rheumatology (Oxford) 2009;48:1008-11
Arnaud L, Kahn JE, Girszyn N, Piette AM, Bletry O. Takayasu’s arteritis: An update on physiopathology. Eur J Intern Med 2006;17:241-6
Numano F, Kobayashi Y, Maruyama Y, Kakuta T, Miyata T, Kishi Y. Takayasu arteritis: clinical characteristics and the role of genetic factors in its pathogenesis. Vasc Med 1996;1:227-33
Keser G, Aksu K, Direskeneli H. Takayasu arteritis: an update Turk J Med Sci 2018;48:681-97
Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990;33:1129-34
Mekinian A, Comarmond C, Resche-Rigon M, Mirault T, Kahn JE, Lambert M, et al. Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients. Circulation 2015;132:1693-700
Pazzola G, Muratore F, Pipitone N, Crescentini F, Cacoub P, Boiardi L, et al. Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. Rheumatology (Oxford) 2017 Jul 18
Saadoun D, Lambert M, Mirault T, Resche-Rigon M, Koskas F, Cluzel P, et al. Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience. Circulation 2012;125:813-9
Osman M, Aaron S, Noga M, Yacyshyn E. Takayasu’s arteritis progression on anti-TNF biologics: a case series. Clin Rheumatol 2011;30:703-6
Souabni L, Ben Abdelghani K, Jradi S, Zakraoui L. Takayasu’s arteritis occurring under TNF-a blockers: a new paradoxical effect? BMJ Case Rep 2014;2014
Mariani N, So A, Aubry-Rozier B. Two cases of Takayasu’s arteritis occurring under anti-TNF therapy. Joint Bone Spine 2013;80:211-3
Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007;13:1323-3